Frontiers in Microbiology (Feb 2023)

An adenovirus-vectored RVF vaccine confers complete protection against lethal RVFV challenge in A129 mice

  • Meng Hao,
  • Ting Bian,
  • Guangcheng Fu,
  • Yi Chen,
  • Ting Fang,
  • Chuanyi Zhao,
  • Shuling Liu,
  • Changming Yu,
  • Jianmin Li,
  • Jianmin Li,
  • Wei Chen

DOI
https://doi.org/10.3389/fmicb.2023.1114226
Journal volume & issue
Vol. 14

Abstract

Read online

Instruction: Rift valley fever virus (RVFV) is a mosquito-transmitted bunyavirus that causes severe disease in animals and humans. Nevertheless, there are no vaccines applied to prevent RVFV infection for human at present. Therefore, it is necessary to develop a safe and effective RVFV vaccine.Methods: We generated Ad5-GnGcopt, a replication-deficient recombinant Ad5 vector (human adenovirus serotype 5) expressing codon-optimized RVFV glycoproteins Gn and Gc, and evaluated its immunogenicity and protective efficacy in mice.Results and Discussion: Intramuscular immunization of Ad5-GnGcopt in mice induces strong and durable antibody production and robust cellular immune responses. Additionally, a single vaccination with Ad5-GnGcopt vaccination can completely protect interferon-α/β receptor-deficient A129 mice from lethal RVFV infection. Our work indicates that Ad5-GnGcopt might represent a potential vaccine candidate against RVFV. However, further research is needed, first to confirm its efficacy in a natural animal host, and ultimately escalate as a potential vaccine candidate for humans.

Keywords